Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

摘要

Background:Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infections and the resulting disease,coronavirus disease 2019(Covid-19),have spread to millions of persons worldwide.Multiple vaccine candidates are under development,but no vaccine is currently available.Interim safety and immunogenicity data about the vaccine candidate BNT162b1 in younger adults have been reported previously from trials in Germany and the United States.